Nearly 2 to 1 patients prefer AirFit F30 over the current minimal-contact full face market leader SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback